Trial Outcomes & Findings for The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome (NCT NCT01102270)

NCT ID: NCT01102270

Last Updated: 2017-04-18

Results Overview

number of respiratory events per hour of sleep Respiratory events last for at least 10 seconds and are associated with a decrease in blood oxygenation or a cortical arosual from sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \> 30/h = severe

Recruitment status

COMPLETED

Study phase

EARLY_PHASE1

Target enrollment

17 participants

Primary outcome timeframe

8 hour In-Laboratory Polysomnogram (PSG)

Results posted on

2017-04-18

Participant Flow

subjects recruited 2008-2010 from clinics and ads

Participant milestones

Participant milestones
Measure
Eszopiclone First, Then Sugar Pill
Eszopiclone : 3mg tablet once prior to sleep followed by sugar pill (placebo) 1 week later
Sugar Pill First, Then Eszopiclone
Placebo : 1 placebo capsule prior to sleep then 3mg eszopiclone 1 week later
Overall Study
STARTED
8
9
Overall Study
COMPLETED
8
9
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Study Participants
n=17 Participants
all study participants who received all interventions
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
17 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age, Continuous
45 years
STANDARD_DEVIATION 15 • n=5 Participants
Sex: Female, Male
Female
7 Participants
n=5 Participants
Sex: Female, Male
Male
10 Participants
n=5 Participants
Region of Enrollment
United States
17 participants
n=5 Participants

PRIMARY outcome

Timeframe: 8 hour In-Laboratory Polysomnogram (PSG)

number of respiratory events per hour of sleep Respiratory events last for at least 10 seconds and are associated with a decrease in blood oxygenation or a cortical arosual from sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \> 30/h = severe

Outcome measures

Outcome measures
Measure
Eszopiclone
n=17 Participants
Eszopiclone : 3mg tablet once prior to sleep
Sugar Pill
n=17 Participants
Placebo : 1 placebo capsule prior to sleep
Apnea Hypopnea Index
24 events per hour of sleep
Standard Error 4
31 events per hour of sleep
Standard Error 5

SECONDARY outcome

Timeframe: 8 hour In-Laboratory Polysomnogram (PSG)

quantified using an epiglottic pressure transducer in CmH2O

Outcome measures

Outcome measures
Measure
Eszopiclone
n=17 Participants
Eszopiclone : 3mg tablet once prior to sleep
Sugar Pill
n=17 Participants
Placebo : 1 placebo capsule prior to sleep
Arousal Threshold
-18 cmH2O
Interval -22.1 to -15.1
-14 cmH2O
Interval -19.9 to 10.9

SECONDARY outcome

Timeframe: 8 hour In-Laboratory Polysomnogram (PSG)

Nadir overnight oxygen saturation (%)

Outcome measures

Outcome measures
Measure
Eszopiclone
n=17 Participants
Eszopiclone : 3mg tablet once prior to sleep
Sugar Pill
n=17 Participants
Placebo : 1 placebo capsule prior to sleep
Nadir Overnight Oxygen Saturation
80 % oxygen saturation
Standard Error 1
80 % oxygen saturation
Standard Error 1

SECONDARY outcome

Timeframe: 8 hour In-Laboratory Polysomnogram (PSG)

total sleep duration

Outcome measures

Outcome measures
Measure
Eszopiclone
n=17 Participants
Eszopiclone : 3mg tablet once prior to sleep
Sugar Pill
n=17 Participants
Placebo : 1 placebo capsule prior to sleep
Sleep Duration
6.8 hours of sleep
Standard Error 0.2
5.4 hours of sleep
Standard Error 0.4

Adverse Events

Eszopiclone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Sugar Pill

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Atul Malhotra

Brigham and Women's Hospital

Phone: 6177326488

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place